AGILE THERAPEUTICS, INC.

Consensus Agile Therapeutics, Inc.

Equities

AGRX

US00847L3087

Market Closed - OTC Markets Other stock markets 03:52:57 2024-04-15 pm EDT			5-day change	1st Jan Change
0.3704 ^USD	+1.74%		-5.99%	-81.01%

Mar. 28	Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	MT

Evolution of the average Target Price on Agile Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

56f.4vAv2gwMxkNxBwOgEdOKkyNmQh3poCxnF16RKK6xV14.k51Ns154_zpIdGiVYpu_vlEHd3_a6FsVfm_pR9r9IRCNtUa4U22RNihiNw~299ab14826eb16b213b83148a6a4094b

Analyst Recommendations on Agile Therapeutics, Inc.

Maxim Downgrades Agile Therapeutics to Hold From Buy	Mar. 18	MT
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	23-09-22	MT
HC Wainwright Cuts Price Target on Agile Therapeutics to $3 From $5, Maintains Buy Rating	22-12-30	MT
Maxim Upgrades Agile Therapeutics to Buy from Hold, Sets $1 Price Target	22-07-26	MT
HC Wainwright Raises Agile Therapeutics' Price Target to $5 From $2.50, Maintains Buy Rating	22-07-11	MT
Maxim Downgrades Agile Therapeutics to Hold From Buy	22-04-08	MT
Oppenheimer Adjusts Agile Therapeutics' Price Target to $1.50 From $4, Maintains Outperform Rating	22-03-31	MT
AGILE THERAPEUTICS : HC Wainwright Adjusts Agile Therapeutics PT to $3.50 From $7, Maintains Buy Rating	21-09-13	MT
AGILE THERAPEUTICS' : Price Target Trimmed to $5 From $6 by RBC on Equity Dilution; Outperform, Speculative Risk Maintained	21-07-27	MT
AGILE THERAPEUTICS : Oppenheimer Adjusts Price Target for Agile Therapeutics to $4 From $6, Maintains Outperform Rating	21-07-22	MT
AGILE THERAPEUTICS : Oppenheimer Adjusts Agile Therapeutics' Price Target to $6 From $10, Maintains Outperform Rating	21-05-05	MT
AGILE THERAPEUTICS : Oppenheimer Adjusts Agile Therapeutics PT to $10 From $12, Maintains Outperform Rating	20-12-08	MT
AGILE THERAPEUTICS : HC Wainwright Adjusts Agile Therapeutics' Price Target to $7 From $6, Keeps at Buy	20-12-08	MT

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

HOLD

Number of Analysts

1

Last Close Price

0.3704

Average target price

-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Agile Therapeutics, Inc.

Maxim
HC Wainwright
Oppenheimer
RBC Capital Markets

Ratings for Agile Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Stock Market
Equities
AGRX Stock
Consensus Agile Therapeutics, Inc.

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer